Bulbeck Mill, Mill lane, Barrington Cambs. CB22 7QY, United Kingdom - 07-04-2022 (PR Distribution™) -
The study was awarded funding by the NIHR under their Invention for Innovation (i4i) programme.
Cambridge, United Kingdom - Cydar Medical, in partnership with King’s College London, has today announced it has initiated the ARIA Study: a randomised controlled trial to assess the clinical, technical and cost-effectiveness of a cloud-based, ARtificially Intelligent image fusion system in comparison to standard treatment to guide endovascular Aortic aneurysm repair (ARIA),
Endovascular aneurysm repair (EVAR) is an alternative to open aortic surgery due to perceived advantages in patient survival, reduced post-operative complications and shorter hospital lengths of stay.(1) Despite these potential advantages, there is still significant variability in pre-operative planning and sizing, problems associated with imprecise visualisation and device positioning intra-operatively, and inconsistent patient outcomes.
“Our central hypothesis is that digital technology - specifically cloud-computing and artificial intelligence (AI), can be used to assess and learn from large volumes of data to inform clinical decision making and has the potential to improve the predictability of individual patient outcomes and the consistency of outcomes in the NHS, “said Dr Rachel Clough, Principal Investigator of the ARIA Study and Clinical Senior Lecturer from King’s College London.
The randomised trial will enrol 340 patients in 10 sites across the UK with a clinical diagnosis of abdominal aortic or thoracoabdominal aortic aneurysm (AAA and TAAA respectively) suitable for endovascular treatment. The trial will follow patients for one year and assess the effect of Cydar EV Maps on clinical-, technical- and cost-effectiveness in comparison to standard treatment in endovascular aortic aneurysm repair, used for both standard and complex devices.
The study was initiated with the first patient enrolled at the Liverpool University Hospitals NHS Foundation Trust. “Cydar EV Maps is a game-changing technology for vascular navigation. The ARIA study provides a unique opportunity to demonstrate the benefits like reduced procedure time and reduction to radiation exposure, although some of the more subtle benefits related to procedural quality and reduced operator fatigue may never be directly measured but are obvious as an operator,” said Dr Simon Neequaye, Principal Investigator at the Liverpool University Hospital NHS Foundation Trust.
Cydar EV Maps is the first product from Cydar Medical’s integrated software solutions system. It is simple to integrate with the existing imaging hardware that is present in all hospitals undertaking endovascular surgery.
Cydar EV Maps is currently available in the EU, UK and US. It is certified Software-as-a-Medical Device with an EU CE mark and U.S. FDA 510(k) clearance.
For further information, please contact:
Paul Hardwick
Commercial Director, Cydar
Email: paul.hardwick@cydar.co.uk
About Cydar
Cydar specializes in medical computer vision, machine learning and cloud high-performance computing. Cydar EV Maps is cloud-based software that generates patient specific 3D Maps of soft tissue vasculature to support more effective image guided, minimally invasive endovascular surgery. The system comprises pre-operative procedure planning functionality and real time, AI enabled 3D intra-operative imaging and procedure guidance, with procedure video capture and post procedure review functions.
When guidewires and instruments deform blood vessel, the real-time imaging updates the Map to match the new, deformed patient anatomy. This results in an accurate 3D Map on the screen throughout a procedure. The Cydar EV Maps platform also allows post procedure outcome analysis. The result of this integration of procedure planning, guidance and review is that surgeons can work more accurately and efficiently – enabling an ~50%(2) reduction in radiation exposure, a significant reduction in fluoroscopy time and reducing procedure times by more than 20%(3) while helping achieve better outcomes for patients.
Cydar’s Surgical Augmented Intelligence technology is learning from every case to develop a deeper understanding of surgery. Headquartered in Cambridge, UK, Cydar’s focus is to build a future where all procedures proceed exactly as planned News about Cydar can be found at www.cydarmedical.com/news
King’s College London
King's College London is one of the top 35 UK universities in the world and one of the top 10 in Europe (QS World University Rankings, 2020/21) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff.
King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2021 Research Excellence Framework (REF), King’s maintained its sixth position for ‘research power’ in the UK. King’s has also been rated third amongst multidisciplinary institutions for impact, with 67.8% of its research impact rated outstanding.
Since our foundation, King’s students and staff have dedicated themselves in the service of society. King’s will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King's strategic vision to take the university to the 200th anniversary of its founding.
World-changing ideas. Life-changing impact: https://www.kcl.ac.uk/news/headlines.aspx
NIHR
The mission of the NIHR is to improve the health and wealth of the nation through research. We do this by:
• Funding high quality, timely research that benefits the NHS, public health and social care.
• Investing in world-class expertise, facilities, and a skilled delivery workforce to translate discoveries into improved treatments and services.
• Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research.
• Attracting, training and supporting the best researchers to tackle complex health and social care challenges.
• Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system.
• Funding applied global health research and training to meet the needs of the poorest people in low- and middle-income countries.
NIHR is funded by the Department of Health and Social Care. Its work in low- and middle-income countries is principally funded through UK Aid from the UK government.
References:
1 Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004;364(9437):843-8.
2 Maurel B, Martin?Gonzalez T, Chong D, et al. A prospective observational trial of fusion imaging in infrarenal aneurysms. J Vasc Surg. 2018;68:1706?1713.
3 Shortell C, Veith Symposium New York, 2017
Media Contacts:
Company Name: Cydar Medical
Full Name: Cynthia Azucena
Phone: +447969366582
Email Address: Send Email
Website: http://www.cydarmedical.com
For the original news story, please visit https://www.prdistribution.com/news/cydar-medical-and-king-s-college-london-initiates-randomized-controlled-trial-of-cydar-ev-maps/9207438.
